RIGL News and Press, Rigel Pharmaceuticals Inc. From 05/05/25

2025-05-05 17:20:34 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability Rigel Looks Interesting, But Let's Wait For A Lower Price Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript Rigel settles patent...

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...

2025-04-04 15:31:25 ET Summary RIGL is a profitable, three-drug company, reporting a net income of $17.5M for 2024. RIGL's three marketed drugs, Tavalisse (fostamatinib) remains the major generator of net product sales, accounting for two-thirds of Q4'24's net product sales. A...

2025-03-27 09:59:35 ET More on Rigel Pharmaceuticals Rigel Looks Interesting, But Let's Wait For A Lower Price Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents Rig...

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation PR Newswire SOUTH SAN FRANCISCO, Calif. , March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it h...

2025-03-11 09:57:33 ET Summary Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 shows promising preliminary data in lower-ri...

2025-03-10 08:06:32 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents Rigel Pharmaceuticals sets 2025 sales outlook above estimates ...

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors PR Newswire SOUTH SAN FRANCISCO, Calif. , March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of ...

2025-03-04 23:29:05 ET Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Conference Call March 4, 2025 16:30 ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Of...

2025-03-04 16:03:27 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents Rigel Pharmaceuticals sets 2025 sales outlook above estimates Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Histor...